Genevant
- Company typePrivate
- Founded2018
- HeadquartersVancouver, Canada
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Genevant does
Genevant Sciences is a B2B technology licensing company focused on nucleic acid drug delivery, founded in 2018 as a spinout from Arbutus Biopharma and operating as a subsidiary of Roivant Sciences Ltd. (NASDAQ: ROIV). The company's core technology is a Lipid Nanoparticle (LNP) delivery platform with over 20 years of development history that enables functional delivery of mRNA, siRNA, and gene editing payloads, and which is the delivery mechanism behind patisiran/ONPATTRO, the first and only approved systemic RNA-LNP product. Genevant also operates a Ligand Conjugate Delivery Platform featuring multivalent N-acetylgalactosamine (GalNAc) motifs for hepatocyte delivery and novel structures for extrahepatic organs, with next-generation endosomal release functionality demonstrating a 10x potency advantage in nonhuman primates.
Genevant monetizes its technology through nonexclusive licensing agreements with pharmaceutical and biotechnology counterparties. Deal structures include upfront payments, development and regulatory milestone payments, and tiered royalties, with total potential deal values ranging from $100 million to $238 million per partner. The company's patent estate covers over 700 issued or pending patents worldwide and is the foundation of an active patent enforcement program, including a March 2026 $2.25 billion global settlement with Moderna (comprising $950 million upfront and up to $1.3 billion contingent on appeal) and ongoing U.S. litigation against Pfizer/BioNTech. Manufacturing capability extends to kilogram-scale nucleic acid batches, supporting future commercialization by licensees.
Genevant serves a horizontal customer segment of pharmaceutical and biotechnology companies developing mRNA therapeutics, siRNA drugs, gene editing treatments, and self-amplifying RNA vaccines, with named partners including BioNTech, Novo Nordisk, Editas Medicine, Tome Biosciences, Korro Bio, Gritstone bio, Repair Biotechnologies, and Epitopea. In addition to licensing, Genevant is advancing two proprietary late-preclinical candidates: GNV069 (siRNA-GalNAc for liver fibrosis) and GNV705 (siRNA-GalNAc for acromegaly). The company maintains offices in Vancouver (Canada), Cambridge (USA), and Basel (Switzerland), with the latter serving as its European headquarters.
Genevant firmographics
Firmographics- Name
- Genevant
- Legal name
- Genevant Sciences, Inc.
- Website
- https://genevant.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Genevant industry classification
Industry- Product category
- Drug Delivery Technology Licensing
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Patent Owners & Lessors (6794)
- akta.pro primary industry
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
- akta.pro secondary industry
- Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)
Keywords
Where Genevant is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
Genevant business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Technology Licensing: Genevant generates revenue by granting nonexclusive licenses to its LNP technology and other delivery platforms to pharmaceutical and biotechnology companies. Licenses cover specified fields and indications with upfront payments, development and regulatory milestones, and tiered royalties on future product sales.
- Milestone Payments: Collaborations include upfront payments, contingent milestone payments tied to development, regulatory, and commercial achievements, and tiered royalties on product sales. Deals range from $100M to $238M+ in total potential value.
- Settlement Proceeds: Genevant and Arbutus Biopharma received $950 million upfront payment from Moderna settlement in July 2026, with additional $1.3 billion contingent on favorable appellate ruling. Roivant receives approximately two-thirds of settlement proceeds.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Genevant product offering
Product offeringCore offering
Genevant Sciences is a nucleic acid delivery technology company that develops and licenses proprietary Lipid Nanoparticle (LNP) and Ligand Conjugate delivery platforms enabling functional delivery of mRNA, siRNA, and gene editing payloads. The company generates revenue by granting nonexclusive licenses to pharmaceutical and biotechnology partners for use of its delivery platforms and patent estate in specified therapeutic fields, supplemented by two proprietary late-preclinical product candidates (GNV069 and GNV705).
Product overview
Genevant Sciences operates as a technology-focused nucleic acid delivery company offering two core proprietary platforms: the Lipid Nanoparticle (LNP) Delivery Platform and the Ligand Conjugate Delivery Platform. These platforms enable delivery of diverse nucleic acid payloads including mRNA, siRNA, and gene editing constructs. The company also maintains two proprietary late preclinical product candidates: GNV069 (siRNA-GalNAc for liver fibrosis) and GNV705 (siRNA-GalNAc for acromegaly). Genevant's business model centers on selectively licensing its platforms and technologies to pharmaceutical and biotechnology partners while advancing its own proprietary candidates.
Differentiator
Problem solved
Functional benefit
Products and services
- LNP Delivery Platform
- Ligand Conjugate Delivery Platform
- GNV069
- GNV705
Quantifiable outcome
- First and only approved systemic RNA-LNP product (patisiran/ONPATTRO)
- +4 more outcomes
Companies that use Genevant
Customer profileSegments1 record
Ideal customer profiles1 record
Genevant technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Genevant partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core, former core, major, significant and ongoing.
- Arbutus BiopharmacoreOngoing strategic relationship where Arbutus is Genevant's exclusive licensee for LNP delivery technology. Arbutus retains ownership stake in and license agreement with Genevant. Both companies jointly pursued patent litigation against Moderna and Pfizer/BioNTech. Arbutus is evaluating return of capital to shareholders in Q3 2026 in conjunction with Moderna settlement payment. Ongoing litigation against Pfizer/BioNTech continues in the U.S.
- Modernaformer core$2.25 billion global settlement resolving all U.S. and international patent infringement litigation. Moderna to pay $950 million upfront (July 2026) and additional $1.3 billion contingent on Section 1498 appeal resolution. Moderna granted global nonexclusive license to Genevant LNP technology for SM-102-containing mRNA vaccines for infectious disease. Settlement includes judgment of infringement and no invalidity on four Genevant/Arbutus patents. Pfizer/BioNTech litigation remains ongoing.
- EpitopeamajorCollaboration and nonexclusive license agreement to develop novel mRNA-LNP immunotherapies targeting Epitopea's proprietary aberrantly-expressed tumor specific antigens (aeTSAs) called Cryptigens for an undisclosed oncology indication. Genevant eligible to receive up to $123.5 million in upfront and contingent milestone payments per product and tiered royalties ranging from mid to high single digits on future product sales.
- Editas MedicinemajorCollaboration and nonexclusive license agreement combining Editas Medicine's CRISPR Cas12a genome editing systems with Genevant's LNP technology for in vivo gene editing medicines directed to two undisclosed targets. Genevant eligible to receive up to $238 million in upfront and contingent milestone payments and tiered royalties on future product sales.
- Repair BiotechnologiessignificantCollaboration and nonexclusive license agreement combining Repair's Cholesterol Degrading Platform (CDP) mRNA technology with Genevant's LNP technology for development of potential novel treatment for atherosclerosis. Genevant eligible to receive up to $107 million in upfront and contingent milestone payments per product and tiered royalties ranging from mid to high single digits on future product sales.
- Tome BiosciencessignificantCollaboration and nonexclusive license agreement combining Genevant's LNP technology with Tome's programmable genomic integration (PGI) technology to develop in vivo gene editing treatment for an undisclosed rare monogenic liver disorder. Total deal value of $114.3 million plus tiered royalties on future product sales.
- Novo NordiskmajorCollaboration and nonexclusive license agreement combining Genevant's LNP technology with Novo Nordisk's mRNA-based megaTAL technology to develop in vivo gene editing treatment for hemophilia A. Agreement arose from exercise of option under prior agreement between Genevant and 2seventy bio subsequently assigned to Novo Nordisk.
- Gritstone biomajorMulti-year, multi-pathogen option-based agreement for non-exclusive license to Genevant's LNP technology for use with Gritstone bio's self-amplifying RNA (samRNA) vaccines. Genevant eligible to receive option maintenance and exercise fees in single digit millions, up to $136 million in contingent milestone payments per product (subject to increase for multi-pathogen products), and royalties ranging from mid to high single digits. Genevant LNP technology used in Gritstone's COVID-19 vaccine candidate behind BARDA award.
- Korro BiosignificantCollaboration agreement combining Korro's RNA editing platform with Genevant's LNP technology to develop therapeutic for Alpha-1 Antitrypsin Deficiency (AATD). Terms not disclosed.
- Pfizer/BioNTechongoingOngoing patent infringement lawsuit in the United States for use of Arbutus/Genevant LNP technology in Pfizer/BioNTech's Comirnaty COVID-19 vaccine. Comirnaty sales represent approximately 2/3 of global COVID-mRNA vaccine sales to date. Favorable Markman ruling issued in September 2025.
- Roivant SciencescoreGenevant Sciences is a subsidiary of Roivant Sciences Ltd. (NASDAQ: ROIV). Roivant hosts investor calls and manages capital allocation including share repurchase programs from settlement proceeds. Roivant holds ownership stakes in both Arbutus and Genevant.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Genevant competitors and assessment
Company assessmentDirect peers
- Arbutus Biopharma: Arbutus is Genevant's closest direct peer and exclusive licensee for LNP delivery technology. Both companies originated from the same nucleic acid delivery lineage, co-enforce the LNP patent estate (joint litigation with Moderna and Pfizer/BioNTech), and share economics from the $2.25B Moderna settlement.
- Acuitas Therapeutics: Acuitas develops ionizable lipid-based LNP technology for delivery of mRNA and other nucleic acid therapeutics and is the LNP supplier behind Pfizer/BioNTech's Comirnaty. It is the primary competing LNP platform company and the most direct functional peer to Genevant.
Broad incumbents
- Alnylam Pharmaceuticals: Alnylam pioneered GalNAc-conjugate siRNA delivery (the foundation of Genevant's Ligand Conjugate Platform) and is the leading commercial siRNA company. It is comparable as a broad incumbent in RNA-targeted delivery and therapeutics.
- Ionis Pharmaceuticals: Ionis is a leading RNA-targeted therapeutics company developing antisense oligonucleotides across multiple disease areas. While it uses different delivery chemistry, it is comparable as a broad incumbent in RNA-based drug development and represents the same end-customer profile as Genevant's platform.
Emerging players
- Precision NanoSystems (Cytiva): Precision NanoSystems (now part of Cytiva) develops microfluidic-based LNP formulation technology and instrumentation used by RNA therapeutics developers. It is comparable as an emerging platform player in LNP delivery, though more focused on tools/formulation equipment than therapeutic applications.
- Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapeutics using its proprietary TRiM™ delivery platform that, like Genevant's Ligand Conjugate, targets extrahepatic tissues. It is comparable as an emerging player with its own delivery platform for nucleic acid therapeutics.
- CureVac: CureVac is an mRNA therapeutics company developing vaccines and therapeutics, with its own LNP formulation expertise. It is comparable as a nucleic acid medicines developer that could be a Genevant platform licensee or competitor.
Others
- BioNTech: BioNTech is both a Genevant licensee (nonexclusive LNP access) and the target of ongoing patent litigation (Comirnaty). It is comparable as a major customer/litigation counterparty in the LNP value chain.
- Moderna: Moderna is a Genevant licensee under the March 2026 settlement and former litigation counterparty. It is comparable as both a major customer (nonexclusive SM-102 LNP license for infectious disease mRNA vaccines) and a key historical plaintiff.
- Editas Medicine: Editas is a Genevant licensee (up to $238M, October 2024) combining its CRISPR Cas12a systems with Genevant's LNP for in vivo gene editing. It is comparable as a major licensing partner representing the in vivo gene editing customer profile.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Genevant social profiles
Digital presenceGenevant financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genevant leadership team
Management profileNumber of profiles
Profiles7 records
Genevant funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genevant M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genevant
What does Genevant do?
Genevant Sciences is a nucleic acid delivery technology company that develops and licenses proprietary Lipid Nanoparticle (LNP) and Ligand Conjugate delivery platforms enabling functional delivery of mRNA, siRNA, and gene editing payloads. The company generates revenue by granting nonexclusive licenses to pharmaceutical and biotechnology partners for use of its delivery platforms and patent estate in specified therapeutic fields, supplemented by two proprietary late-preclinical product candidates (GNV069 and GNV705).
Is Genevant a public or private company?
Genevant is a private company. It is classified as corporate owned and is currently operating.
When was Genevant founded?
Genevant was founded in 2018. It employs 51 to 100 people.
Where is Genevant based?
Genevant is headquartered in Vancouver, Canada, in the North America region.
How does Genevant make money?
Three revenue lines are on record. Technology Licensing is the primary driver. The others are milestone Payments and settlement Proceeds.
Who are Genevant's main competitors?
Direct peers on record are Arbutus Biopharma and Acuitas Therapeutics. Broad incumbents are Alnylam Pharmaceuticals and Ionis Pharmaceuticals. Emerging players are Precision NanoSystems (Cytiva), Arrowhead Pharmaceuticals and CureVac. Others are BioNTech, Moderna and Editas Medicine.
Does Genevant have an API?
No public API is recorded for Genevant.
What industry is Genevant in?
Genevant's product category is Drug Delivery Technology Licensing. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development), with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 541714 and its SIC code is 8731.